Loading...
LAB B logo

Genomma Lab Internacional, S.A.B. de C.V.BMV:LAB B Stock Report

Market Cap Mex$14.3b
Share Price
Mex$14.71
Mex$26.8
45.1% undervalued intrinsic discount
1Y-32.6%
7D-6.1%
1D
Portfolio Value
View

Genomma Lab Internacional, S.A.B. de C.V.

BMV:LAB B Stock Report

Market Cap: Mex$14.3b

Genomma Lab Internacional. de (LAB B) Stock Overview

Provides pharmaceutical and personal care products primarily in Mexico and internationally. More details

LAB B fundamental analysis
Snowflake Score
Valuation4/6
Future Growth3/6
Past Performance2/6
Financial Health4/6
Dividends3/6

LAB B Community Fair Values

Create Narrative

See what 14 others think this stock is worth. Follow their fair value or set your own to get alerts.

Genomma Lab Internacional, S.A.B. de C.V. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Genomma Lab Internacional. de
Historical stock prices
Current Share PriceMex$14.71
52 Week HighMex$23.60
52 Week LowMex$14.66
Beta0.15
1 Month Change-13.93%
3 Month Change-16.85%
1 Year Change-32.55%
3 Year Change2.44%
5 Year Change-30.38%
Change since IPO79.61%

Recent News & Updates

New Narrative Mar 06

Productivity Savings And Channel Expansion Will Support A Stronger Long Term Earnings Profile

Catalysts About Genomma Lab Internacional. de Genomma Lab Internacional.

Recent updates

New Narrative Mar 06

Productivity Savings And Channel Expansion Will Support A Stronger Long Term Earnings Profile

Catalysts About Genomma Lab Internacional. de Genomma Lab Internacional.
New Narrative Feb 20

Seasonal Volatility And Cost Cuts Will Test Margin Ambitions Yet Support A Cautious Upside View

Catalysts About Genomma Lab Internacional. de Genomma Lab Internacional.
Analysis Article Dec 12

Genomma Lab Internacional. de (BMV:LABB) Has Announced A Dividend Of MX$0.20

The board of Genomma Lab Internacional, S.A.B. de C.V. ( BMV:LABB ) has announced that it will pay a dividend of...
Analysis Article Oct 12

Potential Upside For Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Not Without Risk

With a price-to-earnings (or "P/E") ratio of 9.3x Genomma Lab Internacional, S.A.B. de C.V. ( BMV:LABB ) may be sending...
Analysis Article Sep 15

Genomma Lab Internacional. de (BMV:LABB) Is Paying Out A Dividend Of MX$0.20

The board of Genomma Lab Internacional, S.A.B. de C.V. ( BMV:LABB ) has announced that it will pay a dividend of...
Analysis Article Jun 26

Genomma Lab Internacional. de (BMV:LABB) Is Paying Out A Dividend Of MX$0.20

Genomma Lab Internacional, S.A.B. de C.V. ( BMV:LABB ) has announced that it will pay a dividend of MX$0.20 per share...
Analysis Article May 28

These 4 Measures Indicate That Genomma Lab Internacional. de (BMV:LABB) Is Using Debt Reasonably Well

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article Feb 14

We Think Genomma Lab Internacional. de (BMV:LABB) Can Stay On Top Of Its Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Analysis Article Dec 02

Investors Appear Satisfied With Genomma Lab Internacional, S.A.B. de C.V.'s (BMV:LABB) Prospects

When close to half the companies in Mexico have price-to-earnings ratios (or "P/E's") below 11x, you may consider...
Analysis Article Oct 17

Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article Sep 11

Calculating The Intrinsic Value Of Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB)

Key Insights The projected fair value for Genomma Lab Internacional. de is Mex$21.54 based on 2 Stage Free Cash Flow to...
Analysis Article Jul 12

With Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) It Looks Like You'll Get What You Pay For

When close to half the companies in Mexico have price-to-earnings ratios (or "P/E's") below 13x, you may consider...
Analysis Article May 31

These 4 Measures Indicate That Genomma Lab Internacional. de (BMV:LABB) Is Using Debt Reasonably Well

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article Jan 29

Here's Why Genomma Lab Internacional. de (BMV:LABB) Can Manage Its Debt Responsibly

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Analysis Article Nov 07

Is Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Trading At A 49% Discount?

Key Insights Genomma Lab Internacional. de's estimated fair value is Mex$28.31 based on 2 Stage Free Cash Flow to...
Analysis Article Mar 31

Is Genomma Lab Internacional. de (BMV:LABB) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article Feb 24

Is Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Trading At A 32% Discount?

Key Insights Using the 2 Stage Free Cash Flow to Equity, Genomma Lab Internacional. de fair value estimate is Mex$22.94...
Analysis Article Dec 07

Does Genomma Lab Internacional. de (BMV:LABB) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Analysis Article Sep 24

Rainbows and Unicorns: Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Analysts Just Became A Lot More Optimistic

Shareholders in Genomma Lab Internacional, S.A.B. de C.V. ( BMV:LABB ) may be thrilled to learn that the analysts have...
Analysis Article Aug 01

Analysts Just Made A Major Revision To Their Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Revenue Forecasts

The analysts covering Genomma Lab Internacional, S.A.B. de C.V. ( BMV:LABB ) delivered a dose of negativity to...
Analysis Article Jul 27

Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Analysis Article Mar 22

Here's Why Genomma Lab Internacional. de (BMV:LABB) Can Manage Its Debt Responsibly

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article Feb 15

Are Investors Undervaluing Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) By 44%?

Does the February share price for Genomma Lab Internacional, S.A.B. de C.V. ( BMV:LABB ) reflect what it's really...
Analysis Article Nov 24

Genomma Lab Internacional. de (BMV:LABB) Seems To Use Debt Quite Sensibly

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Shareholder Returns

LAB BMX PharmaceuticalsMX Market
7D-6.1%1.5%-3.1%
1Y-32.6%17.8%12.9%

Return vs Industry: LAB B underperformed the MX Pharmaceuticals industry which returned 17.8% over the past year.

Return vs Market: LAB B underperformed the MX Market which returned 12.9% over the past year.

Price Volatility

Is LAB B's price volatile compared to industry and market?
LAB B volatility
LAB B Average Weekly Movement5.9%
Pharmaceuticals Industry Average Movement6.4%
Market Average Movement4.0%
10% most volatile stocks in MX Market6.1%
10% least volatile stocks in MX Market2.6%

Stable Share Price: LAB B's share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: LAB B's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of MX stocks.

About the Company

FoundedEmployeesCEOWebsite
19961,643Juan Marco Sparvieriwww.genommalab.com

Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Mexico and internationally. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products to prevent hair loss, ointment for muscle pain, anti-fungal treatments for the relief of colitis, products to counter stress levels, anti-wrinkles, antacids, anti-ulcers, anti-flu, protection and improvement products, treatments against hemorrhoids, against varicose veins, osteoarthritis, ophthalmic medications, infant nutrition, and others. Genomma Lab Internacional, S.A.B. de C.V. was incorporated in 1996 and is based in Mexico City, Mexico.

Genomma Lab Internacional, S.A.B. de C.V. Fundamentals Summary

How do Genomma Lab Internacional. de's earnings and revenue compare to its market cap?
LAB B fundamental statistics
Market capMex$14.35b
Earnings (TTM)Mex$1.60b
Revenue (TTM)Mex$17.33b
8.9x
P/E Ratio
0.8x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LAB B income statement (TTM)
RevenueMex$17.33b
Cost of RevenueMex$6.41b
Gross ProfitMex$10.91b
Other ExpensesMex$9.31b
EarningsMex$1.60b

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)1.64
Gross Margin62.98%
Net Profit Margin9.25%
Debt/Equity Ratio68.8%

How did LAB B perform over the long term?

See historical performance and comparison

Dividends

5.4%
Current Dividend Yield
36%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/08 19:04
End of Day Share Price 2026/06/05 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Genomma Lab Internacional, S.A.B. de C.V. is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Antonio Hernandez Velez LeijaActinver Case de Bolsa, S.A. de C.V.
Benjamin TheurerBarclays
Robert Ford AguilarBofA Global Research